癌基因特异性T细胞无法清除小鼠淋巴瘤起始B细胞
研究利用可诱导B细胞特异性表达SV40大T抗原(TAg)的转基因小鼠,分析癌基因特异性T细胞在散发性B细胞淋巴瘤发生中的作用。组成性TAg表达导致TAg耐受性CD8+ T细胞和B细胞淋巴瘤发生;而诱导型模型中TAg启动的B细胞未被T细胞清除并长期存在,表明免疫系统无法清除淋巴瘤起始B细胞,保留淋巴瘤发生风险。
要点
- 组成性TAg表达小鼠产生TAg耐受性CD8+ T细胞并发生B细胞淋巴瘤。
- 诱导型小鼠保留TAg competent CD8+ T细胞,少数B细胞表达TAg时淋巴瘤形成极罕见且发生晚。
- 缺乏TAg特异性T细胞时淋巴瘤发生率增加,但TAg启动的B细胞未被清除并长期可检测。
核心结论
- 免疫系统无法清除淋巴瘤起始B细胞,从而保留淋巴瘤发生风险。
研究设计与样本
- 研究生成可B细胞特异性诱导癌基因SV40大T抗原(TAg)的转基因小鼠,分析癌基因特异性T细胞在散发性B细胞淋巴瘤发展中的作用。
主要发现
- CD19-Cre × LoxP-Tag小鼠中组成性TAg表达导致TAg耐受性CD8+ T细胞和B细胞淋巴瘤发生。
- CD19-CreERT2 × LoxP-Tag小鼠在癌基因诱导时保留TAg competent CD8+ T细胞,成年小鼠少数B细胞表达TAg导致生命后期极罕见淋巴瘤形成。
- 缺乏TAg特异性T细胞时淋巴瘤发生率增加,提示T细胞介导的淋巴瘤进展抑制。
- TAg启动的B细胞未被T细胞清除并长期可检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To date, little is known about the interaction between (pre-)malignant B cells and T cells. We generated transgenic mice that allow B cell-specific induction of the oncogene SV40 large T-antigen (TAg) to analyze the role of oncogene-specific T cells during sporadic B-cell lymphoma development. Constitutive TAg expression in CD19-Cre × LoxP-Tag mice resulted in TAg-tolerant CD8+ T cells and development of B-cell lymphomas. In contrast, CD19-CreERT2 × LoxP-Tag mice retained TAg-competent CD8+ T cells at time of oncogene induction and TAg expression in few B cells of adult mice resulted in exceptionally rare lymphoma formation late in life. Increased lymphoma incidence in the absence of TAg-specific T cells suggested T cell-mediated inhibition of lymphoma progression. However, TAg-initiated B cells were not eliminated by T cells and detected long term. Our results demonstrate a failure of the immune system to eradicate lymphoma-initiating B cells, retaining the risk of lymphoma development.
引用
- Hoser D, Schön C, Loddenkemper C, et al. Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells in mice. Blood. 2018. PMID: 30002144. doi:10.1182/blood-2018-02-834036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。